X0306 4 2021-03-12 0 0001770787 10x Genomics, Inc. TXG 0001246406 CRUTCHFIELD BRADFORD C/O 10X GENOMICS, INC. 6230 STONERIDGE MALL ROAD PLEASANTON CA 94588 0 1 0 0 Chief Commercial Officer Class A Common Stock 2021-03-12 4 M 0 17000 1.16 A 51608 D Class A Common Stock 2021-03-12 4 S 0 2100 154.5198 D 49508 D Class A Common Stock 2021-03-12 4 S 0 3807 155.542 D 45701 D Class A Common Stock 2021-03-12 4 S 0 3606 156.5181 D 42095 D Class A Common Stock 2021-03-12 4 S 0 2211 157.704 D 39884 D Class A Common Stock 2021-03-12 4 S 0 3176 158.8517 D 36708 D Class A Common Stock 2021-03-12 4 S 0 2100 159.5128 D 34608 D Stock Option (right to buy) 1.16 2021-03-12 4 M 0 17000 0.00 D 2027-02-03 Class A Common Stock 17000 579000 D The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. This transaction was executed in multiple trades at prices ranging from $154.01 to $154.89. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $155.01 to $156.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $156.09 to $157.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $157.11 to $158.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $158.23 to $159.21. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $159.23 to $159.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This option, originally for 800,000 shares, of which 221,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. /s/ Eric S. Whitaker, as Attorney-in-Fact 2021-03-16